Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | July 07, 2025 | July 10, 2025 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date July 07, 2025 · Filed July 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,846 |
Reported balance
After 2025-07-07 transaction · row 1
1 source rowRow 1 · 2025-07-07 · Sale · Disposed 10,000 · Balance 308,846 F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,220 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 58,220 |
| Common StockSEC Table I · non-derivative | IndirectBy The Maag Family Irrevocable Trust | 349,321 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 349,321 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-11-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,368 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 62,092 · Balance 58,368 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 58,368 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2021 Filed Jan 6, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 10,000 | $6.31 | $63,100.00 |
DisclosureSEC source: 0001217234-21-000004 · wf-form4_160997407328903.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001628280-20-017186 · wf-form4_160746157906959.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,140 Underlying: Common Stock · 10,000 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 571 | $67.10 | $38,316.73 |
DisclosureSEC source: 0001628280-20-017186 · wf-form4_160746157906959.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.97 to $67.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 7,631 | $66.50 | $507,437.08 |
DisclosureSEC source: 0001628280-20-017186 · wf-form4_160746157906959.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,545 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.96 to $66.95, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,798 | $65.58 | $117,913.20 |
DisclosureSEC source: 0001628280-20-017186 · wf-form4_160746157906959.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,176 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.94 to $65.93, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 10,000 | $6.31 | $63,100.00 |
DisclosureSEC source: 0001628280-20-017186 · wf-form4_160746157906959.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,285 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,140 Underlying: Common Stock · 4,285 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,715 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 5,715 shares Expires 2027-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 200 | $54.98 | $10,996.80 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $54.85 to $55.12, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,925 | $54.16 | $104,257.62 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,174 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $53.80 to $54.80, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 7,875 | $53.27 | $419,536.69 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,099 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.75 to $53.53, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 4,285 | $6.31 | $27,038.35 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 00:33 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,715 | $5.90 | $33,718.50 |
DisclosureSEC source: 0001217234-20-000198 · wf-form4_160462280238009.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:11 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · derivative · entry 3 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,340 Underlying: Common Stock · 10,000 shares Expires 2027-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:11 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $42.11 | $421,128.00 |
DisclosureSEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.75 to $42.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:11 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 10,000 | $5.90 | $59,000.00 |
DisclosureSEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,660 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,340 Underlying: Common Stock · 8,660 shares Expires 2027-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,340 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,340 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The shares subject to the option vested in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination, F6 · derivative.exercise_date: (Continued from footnote 5) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,500 | $41.24 | $103,092.50 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.01 to $41.47, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 17,500 | $40.39 | $706,879.25 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,474 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.00 to $41.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 8,660 | $5.90 | $51,094.00 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 11,340 | $5.49 | $62,256.60 |
DisclosureSEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:10 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,992 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · derivative · entry 5 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,340 Underlying: Common Stock · 16,992 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The shares subject to the option vested in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination, F5 · derivative.exercise_date: (Continued from footnote 4) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. F6 · balance_after: The total reported in Column 9 has been adjusted to correct an understatement of total shares subject to the option by 23,158 shares first reflected in a Form 4 filed on April 18, 2019. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:10 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 16,992 | $37.59 | $638,802.35 |
DisclosureSEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.50 to $37.81, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:10 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 16,992 | $5.49 | $93,286.08 |
DisclosureSEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 08, 2020 Filed Sep 8, 2020 21:46 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · derivative · entry 6 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,174 Underlying: Common Stock · 10,000 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F4 · derivative.exercise_date: The shares subject to the option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination, F5 · derivative.exercise_date: (Continued from footnote 3) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| September 08, 2020 Filed Sep 8, 2020 21:46 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 100 | $32.09 | $3,209.00 |
DisclosureSEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. Read SEC document |
| September 08, 2020 Filed Sep 8, 2020 21:46 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 9,900 | $31.68 | $313,609.23 |
DisclosureSEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,074 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.07 to $32.06, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 08, 2020 Filed Sep 8, 2020 21:46 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 10,000 | $5.49 | $54,900.00 |
DisclosureSEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,848 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,281 Underlying: Common Stock · 9,848 shares Expires 2026-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 22, 2017 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,160 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,174 Underlying: Common Stock · 3,160 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F6 · derivative.exercise_date: The shares subject to the option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination, F7 · derivative.exercise_date: (Continued from footnote 6) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 6,600 | $37.11 | $244,906.86 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.7 to $37.545, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,808 | $36.59 | $212,518.79 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,574 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.68 to $36.615, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 600 | $34.86 | $20,913.60 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,382 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.56 to $35.16, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 9,848 | $5.27 | $51,898.96 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,160 | $5.49 | $17,348.40 |
DisclosureSEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,240 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 11 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,129 Underlying: Common Stock · 5,240 shares Expires 2026-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 22, 2017 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,983 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 10 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 1,983 shares Expires 2027-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 27, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,777 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,292 Underlying: Common Stock · 2,777 shares Expires 2027-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $34.49 | $0.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-06 F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on July 6, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $34.21 | $342,098.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.67, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,240 | $5.27 | $27,614.80 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 1,983 | $2.30 | $4,560.90 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 2,777 | $2.80 | $7,775.60 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on July 6, 2021 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,267 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001217234-20-000113 · wf-form4_159372600197491.xml · derivative · entry 5 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,233 Underlying: Common Stock · 9,267 shares Expires 2027-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 27, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:40 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 18,182 | $35.07 | $637,719.10 |
DisclosureSEC source: 0001217234-20-000113 · wf-form4_159372600197491.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,974 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.15, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 9,267 | $2.30 | $21,314.10 |
DisclosureSEC source: 0001217234-20-000113 · wf-form4_159372600197491.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,390 shares acquired by the Reporting Person pursuant to Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 23:44 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,818 | $35.00 | $63,630.00 |
DisclosureSEC source: 0001217234-20-000087 · wf-form4_159191904770738.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,499 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020. Read SEC document |
| June 05, 2020 Filed Jun 5, 2020 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 500 | $33.06 | $16,531.00 |
DisclosureSEC source: 0001217234-20-000080 · wf-form4_159140082565146.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,317 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.01 to $33.10, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.